Breaking News: FDA Approves New Treatment for Hep C (Genotype 1)
November 25, 2013
FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection
Janssen Therapeutics, Division of Janssen Products, LP (Janssen), announced today the U.S. Food and Drug Administration (FDA) has approved OLYSIO™ (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis. OLYSIO™ may benefit patients with chronic hepatitis C, including those who are treatment naive or who have failed prior interferon-based therapy.
Chronic hepatitis C is a blood-borne infectious disease of the liver that affects approximately 3.2 million people in the United States.
Continue reading this entire article:
Telling Your Date You Have Hepatitis C
Exciting Development in Search for Hepatitis C Vaccine